Every 8-K that Amesite Inc. (AMST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AMST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMST filings page.
Amesite Inc. (AMST) disclosed that its next Annual Meeting of Stockholders will be held on December 10, 2026, with details on time, location and agenda to be provided in the forthcoming proxy statement.
Stockholders seeking to include proposals in the proxy statement under Rule 14a-8 must deliver them to the Company’s Secretary by the close of business on September 27, 2026. For other business or director nominations under the Company’s Bylaws (not using Rule 14a-8), notice must also be received by September 27, 2026, and any stockholder intending to solicit proxies in support of director nominees must provide the additional Rule 14a-19 notice by October 13, 2026.
Amesite Inc. (AMST) furnished updated shareholder presentation materials highlighting its AI-powered NurseMagic and LynkMagic platforms for the post‑acute care market, to be used at investor meetings including the H.C. Wainwright 28th Annual Global Investment Conference.
The materials describe a focus on the roughly $1.5T U.S. post‑acute and adjacent care segments, with users in 50 states and 21 countries and strong app ratings (5.0 in the App Store and 4.3 on Google Play). Amesite outlines a progression from a B2C NurseMagic app to enterprise deployments including a ~2,700‑patient census and an owner‑level view across 24 communities. The deck summarizes an April 2026 capital raise totaling $2 in gross proceeds across three tranches, including 696,866 shares sold at $1.435 per share and associated pre‑funded and Series A‑1/A‑2 warrants. It also notes no debt, estimates 16 months of cash burn coverage on hand under conservative assumptions, and positions Amesite as building AI infrastructure that integrates with existing healthcare systems.
Amesite Inc. entered into an At The Market Offering Agreement on July 17, 2026 with H.C. Wainwright & Co., LLC as sales agent, allowing Amesite to offer and sell shares of its common stock from time to time, up to a maximum aggregate offering price defined as the “Maximum Amount” in the agreement. Sales will be made as at-the-market offerings on The Nasdaq Capital Market or by other permitted methods at market prices or as otherwise agreed with the agent, under an effective Form S-3 shelf registration statement and related prospectus supplement.
H.C. Wainwright will use commercially reasonable efforts to execute sales based on Amesite’s instructions, and Amesite is not obligated to sell any shares, nor is the agent obligated to purchase shares on a principal basis. Amesite will pay a 3.0% commission on aggregate gross proceeds from each sale and reimburse specified expenses, including up to $50,000 of the agent’s legal fees and costs. Net proceeds, if any, are intended for general corporate and working capital purposes, with management retaining broad discretion over their allocation. The at-the-market program will end when all shares covered by the agreement are sold or the agreement is terminated under its terms.
Amesite Inc. reported results of its July 13, 2026 annual meeting of stockholders. Stockholders of record on May 22, 2026, when 5,852,985 shares of common stock were outstanding, were entitled to vote. A total of 2,321,797 shares, or approximately 40% of outstanding shares, were represented, constituting a quorum under the company’s bylaws. Stockholders elected Ann Marie Sastry, Ph.D. and Barbie Brewer as Class II directors for three-year terms and ratified Novogradac & Company LLP as independent registered public accounting firm for the year ending June 30, 2026.
Stockholders also approved amending the 2018 Equity Incentive Plan to increase the number of shares available for issuance under the plan by 1,000,000 shares and separately increase the number of shares that may be issued pursuant to the exercise of incentive stock options by 1,000,000 shares. In addition, in accordance with Nasdaq Listing Rule 5635(d), stockholders approved the issuance of an aggregate of 1,393,732 shares of common stock upon exercise of the company’s Series A-1 warrants and an aggregate of 1,393,732 shares of common stock upon exercise of its Series A-2 warrants.
Amesite Inc. disclosed that its NurseMagic™ AI documentation platform has secured a new enterprise customer with an approximately 2,700-patient census, the company’s largest deployment to date. The customer will roll out NurseMagic™ across its workforce to integrate EMR and EVV workflows and reduce administrative tasks that can consume up to 16 hours per caregiver per week.
The company describes this as a step-change in scale that validates NurseMagic™ as core clinical infrastructure for the non-acute/post-acute market. Management also highlights approximately an 18% reduction in operating spend over the last six quarters, a growing base of paying customers, and digital demand metrics including about 4,200 web visits per day and strong inbound interest from providers.
Amesite Inc. entered into multiple financing agreements combining a registered direct offering, a PIPE and an insider-led private placement to raise new equity capital and issue warrants. The company agreed to sell 696,866 registered shares of common stock at $1.435 per share, plus pre-funded warrants and common warrants in a concurrent private placement, and an additional 418,118 shares and matching warrants to officers and directors at $1.435 per share.
The transactions are expected to generate aggregate gross proceeds of about $2 million from the registered direct and PIPE, and about $600,000 from the insider-led private placement, before fees and expenses. If all investor and insider warrants are exercised for cash, Amesite could receive approximately $4 million in additional gross proceeds. The company plans to use net proceeds for working capital and general corporate purposes.
Amesite states that, after these financings, it believes stockholders’ equity will exceed $2.5 million, which is the minimum required to regain compliance with Nasdaq’s stockholders’ equity listing standard, although Nasdaq will continue to monitor ongoing compliance and delisting remains a risk if equity falls below that threshold again.
Amesite Inc. furnished updated shareholder presentation materials outlining progress of its AI-driven NurseMagic platform and broader business. The update highlights large non-acute care markets across home care, home health, hospice, senior living and skilled nursing, and describes disruptive documentation and EMR pricing starting around $1 per patient per month.
The materials note prior revenue momentum, including earlier periods with 240% and 63% revenue growth and Q2 2026 revenues of $108,050, along with a mix of B2C and B2B customers. Amesite also emphasizes having zero corporate debt, several months of operating cash coverage, growing social media reach for NurseMagic, and a sales pipeline of multi-site healthcare organizations.
Amesite Inc. (AMST) furnished a Regulation FD update. The company announced the release of a shareholder update video and provided two exhibits: a press release and the video transcript. The materials are furnished under Item 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings.
Exhibit 99.1 contains the press release dated October 30, 2025, and Exhibit 99.2 contains the transcript. Exhibit 104 is the cover page Inline XBRL.
Amesite Inc. reported a Nasdaq compliance deficiency. On October 28, 2025, the company received a notice that it no longer satisfies Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity. The notice also states the company is not meeting alternative standards, including a $35 million market value of listed securities or $500,000 in net income in the most recent fiscal year or in two of the last three years.
Amesite has 45 calendar days to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 calendar days from the notice date to evidence compliance. If the plan is not accepted or compliance is not achieved within the extension, the company can request a hearing before an independent panel.
The notice has no immediate effect on listing or trading. Amesite’s common stock will continue to trade on the Nasdaq Capital Market under the symbol AMST.
Amesite (Nasdaq: AMST) filed an 8-K on June 26 2025 announcing a change in its independent auditor.
The Audit Committee dismissed Turner, Stone & Company, whose FY 2024 report contained a going-concern paragraph, and appointed Novogradac & Company effective June 24 2025.
- No disagreements with the former auditor were reported.
- Previously disclosed material weaknesses in internal controls over journal entries, stock-based compensation and deferred revenue remain a reportable event.
- Turner Stone’s concurrence letter is filed as Exhibit 16.1.
The auditor switch may influence audit timelines, remediation efforts and investor perception of financial reporting quality.